Since TDP-43 pathology is observed in diseases ranging from ALS and FTLD to Alzheimer’s and Huntington’s disease, therapies that mitigate TDP-43 aggregation and propagation could potentially benefit a broader range of neurodegenerative conditions. This evidence concerns the gene TARDBP and Huntington disease.